Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
CRISPR
Biotech
Trio of biotechs toss programs to discard pile
Adaptimmune Therapeutics, Monte Rosa Therapeutics and Intellia Therapeutics are all throwing programs to the discard pile.
Gabrielle Masson
Nov 9, 2023 11:23am
Intellia preps first ph. 3 trial of in vivo CRISPR therapy in US
Oct 18, 2023 10:15am
New CRISPR diagnostic player VedaBio emerges with $40M start
Oct 17, 2023 10:51am
Chromosome loss from CRISPR-Cas9 stopped by swapping steps
Oct 9, 2023 7:40am
Revvity rolls out base editing reagents for preclinical labs
Sep 28, 2023 1:57pm
Epitope edited CAR-Ts show ability to target all blood cancers
Sep 1, 2023 9:00am
